Antibodies to tissue-type plasminogen activator (t-PA) in patients with inflammatory bowel disease: High prevalence, interactions with functional domains of t-PA and possible implications in thrombosis

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 7, 2006, Pages 1510-1516

  Saibeni, S ^a   Ciscato, C ^a   Vecchi, M ^b   Boscolo Anzoletti, M ^a   Kaczmarek, E ^a   Caccia, S ^a   De Franchis, R ^a   Cugno, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS POLICLINICO SAN DONATO   (Italy)

Author keywords

Antibodies; Crohn's disease; Fibrinolysis; Thrombosis tissue type plasminogen activator; Ulcerative colitis

Indexed keywords

ACUTE PHASE PROTEIN; EPITOPE; FUNGUS ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; IMMUNOSUPPRESSIVE AGENT; MESALAZINE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PHOSPHOLIPID ANTIBODY; STEROID; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGE; AGED; ANTIBODY DETECTION; ARTICLE; BIOCHEMISTRY; BLOOD ANALYSIS; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; DISEASE COURSE; ENTERITIS; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; FEMALE; FIBRINOLYSIS; HUMAN; IN VITRO STUDY; INHIBITION KINETICS; KRINGLE DOMAIN; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN INTERACTION; SEX DIFFERENCE; THROMBOEMBOLISM; ULCERATIVE COLITIS;

ADULT; AUTOANTIBODIES; CASE-CONTROL STUDIES; CATALYTIC DOMAIN; EPITOPES; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFLAMMATORY BOWEL DISEASES; KRINGLES; MALE; MIDDLE AGED; PREVALENCE; PROTEIN STRUCTURE, TERTIARY; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33745269252     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.01970.x     Document Type: Article

References (44)

1. Bargen JA, Barker NW. Extensive arterial and venous thrombosis complicating chronic ulcerative colitis. Arch Intern Med 1936; 58: 17-31.
2. Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: A population-based cohort study. Thromb Haemost 2001; 85: 430-4.
3. Miehsler W, Reinisch W, Valic E, Osterode W, Tillinger W, Feichtenschlager T, Grisar J, Machold K, Scholz S, Vogelsang H, Novacek G. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004; 53: 542-48.
4. Solem CA, Loftus EV Jr, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004; 99: 97-101.
5. Webberly MJ, Hart M, Melikian V. Thromboembolism in inflammatory bowel disease: Role of platelets. Gut 1993; 34: 247-51.
6. Hudson M, Chitolie A, Hutton R, Smiths MSH, Pounder RE, Wakefield AJ. Thrombotic vascular risk factors in inflammatory bowel disease. Gut. 1996; 38: 733-7.
7. Stadnicki A, Kloczko J, Nowak A, Sierka E, Sliwinski Z. Factor XIII subunits in relation to some other hemostatic parameters in ulcerative colitis. Am J Gastroenterol 1991; 86: 690-5.
8. Cattaneo M, Vecchi M, Zighetti ML, Saibeni S, Martinelli I, Omodei P, Mannucci PM, de Franchis R. High prevalence of hyperhomocysteinemia in patients with inflammatory bowel disease: A pathogenic link with thromboembolic complications? Thromb Haemost 1998; 80: 542-5.
9. Oldenburg B, Van Tuyl BAC, van der Griend R, Fijnheer R, van Berge Henegouwen GP. Risk factors for thromboembolic complications in inflammatory bowel disease: The role of hyperhomocysteinaemia. Dig Dis Sci 2005; 50: 235-40.
10. 6 plasma levels, a risk factor for thrombosis, in inflammatory bowel diseases: role of inflammation and correlation with acute phase reactants. Am J Gastroenterol 2003; 98: 112-7.
11. van Bodegraven AA, Tuynman HA, Schoorl M, Kruishoop AM, Bartels PC. Fibrinolytic split products, fibrinolysis, and factor XIII activity in inflammatory bowel disease. Scand J Gastroenterol 1995; 30: 580-5.
12. van Bodegraven AA, Schoorl M, Baak JP, Linskens RK, Bartels PC, Tuynman HA. Hemostatic imbalance in active and quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 487-93.
13. De Jong E, Porte RJ, Knot EA, Verheijen JH, Dees J. Disturbed fibrinolysis in patients with inflammatory bowel disease. A study in blood plasma, colon mucosa, and faeces. Gut 1989; 30: 188-94.
14. Gris JC, Schved JF, Raffanel C, Dubois A, Aguilar-Martinez P, Arnaud A, Sanchez N, Sarlat C, Balmes JL. Impaired fibrinolytic capacity in patients with inflammatory bowel disease. Thromb Haemost 1990; 63: 472-5.
15. Saibeni S, Bottasso B, Spina L, Bajetta M, Danese S, Gasbarrini A, de Franchis R, Vecchi M. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel disease. Am J Gastroenterol 2004; 99: 1966-70.
16. Juhan-Vague I, Valadier J, Alessi MF, Ansaldi J, Philip-Joet C, Holvoet P, Serradigmi A, Collen D. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep-vein thrombosis. Thromb Haemost 1987; 57: 67-72.
17. Eichinger S, Schoenauer V, Weltermann A, Minar E, Bialonczyk C, Hirschl M, Schneider B, Quehenberger P, Kyrle PA. Thrombin activatable fibrinolysis inhibitor (TAFI) and the risk of recurrent venous thromboembolism. Blood 2004; 103: 3773-6.
18. Wiman B. Plasminogen activator inhibitor-1 (PAI-1) in plasma: Its role in thrombotic disease. Thromb Haemost 1995; 74: 71-6.
19. Schroeder T, Chatterjee T, Mehta H. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb Haemost 2002; 88: 1020-5.
20. Cugno M, Cabibbe M, Galli M, Meroni PL, Caccia S, Russo R, Bottasso B, Mannucci PM. Antibodies to tissue-type plasminogen activator (t-PA) in patients with antiphospholipid syndrome: Evidence of interaction between the antibodies and the catalytic domain of t-PA in 2 patients. Blood 2004; 103: 1-6.
21. Cugno M, Dominguez M, Cabibbe M, Bisiani G, Galli M, Angles-Cano E, Agostoni A. Antibodies to tissue-type plasminogen activator in plasma from patients with primary antiphospholipid syndrome. Br J Haematol 2000; 108: 871-5.
22. Ruiz-Arguelles A, Anglès-Cano E, Perez-Romano B, Ruiz-Arguelles GJ, Deleze M, Alarcon-Segovia D, Gaussem P. Serum antibodies to distinct epitopes of tissue-type plasminogen activator (t-PA) in patients with systemic lupus erythematosus. Am J Hematol 1995; 49: 109-14.
23. Fritzler MJ, Hart DA, Wilson D, Garcia-De La Torre I, Salazar-Paramo M, Vasquez-Del Mercado M, Senecal JL, Loyau S, Angles-Cano E. Antibodies to fibrin bound tissue-type plasminogen activator in systemic sclerosis. J Rheumatol 1995; 22: 1688-93.
24. Saxon A, Shanahan FF, Landers C, Ganz T, Targan S. A distinct subset of antineutrophil cytoplasmatic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol 1990; 86: 202-10.
25. Main J, McKenzie H, Yeaman GR, Kerr MA, Robson D, Pennington CR, Parratt D. Antibody to Saccharomyces cerevisiae (baker's yeast) in Crohn's disease. BMJ 1988; 297: 1105-6.
26. Das KM, Dasgupta A, Mandal A, Geng X. Autoimmunity to cytoskeletal protein tropomyosin. J Immunol 1993; 150: 2487-93.
27. Fiocchi C, Roche JK, Paul W, Sapatnekar W. Familial immune reactivity to intestinal epithelial cell-associated components (ECAC) in inflammatory bowel disease. Gastroenterol 1986; 90: 1415.
28. Stocker W, Otte M, Ulrich S, Normann D, Finkbeiner H, Stocker K, Jantschek G, Scriba PC. Autoimmunity to pancreatic juice in Crohn's disease. Scand J Gastroenterol 1987; 22 (Suppl.): 41-52.
29. Aichbichler BW, Petritsch W, Reicht GA, Wenzl HH, Eherer AJ, Hinterleitner TA, Auer-Grumbach P, Krejs GJ. Anti-cardiolipin antibodies in patients with inflammatory bowel disease. Dig Dis Sci 1999; 44: 852-6.
30. Saibeni S, Vecchi M, Valsecchi C, Faioni EM, Razzari C, de Franchis R. Reduced free protein S levels in patients with inflammatory bowel disease. Prevalence, clinical relevance and role of anti-protein S antibodies. Dig Dis Sci 2001; 46: 637-43.
31. Best WR, Becktel JM, Singleton JW, Kern F Jr, Development of a Crohn's disease activity index. Gastroenterol 1976; 70: 439-44.
32. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: Final report of a therapeutic trial. BMJ 1955; 2: 1041-8.
33. Gasche C, Scholmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine EJ, Jewell DP, Rachmilewitz D, Sachar DB, Sandborn WJ, Sutherland LR. A simple classification of Crohn's disease: Report of the Working Party for the World Congress of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000; 6: 8-15.
34. Martin U, Kohnert U, Stern A, Popp F, Fisher S. Comparison of the recombinant Escherichia coli-produced protease domain of tissue-type plasminogen activator with alteplase, reteplase and streptokinase in a canine model of coronary artery thrombolysis. Thromb Haemost 1996; 76: 1096-101.
35. Saibeni S, Folli C, de Franchis R, Borsi G, Vecchi M. Diagnostic role and clinical correlates of anti- Saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (p-ANCA) in Italian patients with inflammatory bowel diseases. Dig Liver Dis 2003; 35: 862-8.
36. Loizou S, McCrea JD, Rudge AC, Reynolds R, Boyle CC, Harris EN. Measurement of anticardiolipin antibodies by enzyme-linked immunosorbent assay: Standardization and quantitation of results. Clin Exp Immunol 1985; 62: 738-44.
37. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulant: An update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185-90.
38. Ieko M, Sawada K, Koike T, Notoya A, Mukai M, Kohno M, Wada N, Itoh T, Yoshioka N. The putative mechanism of thrombosis in antiphospholipid syndrome: Impairment of the protein C and the fibrinolytic systems by monoclonal anticardiolipin antibodies. Semin Thromb Hemost 1999; 25: 503-7.
39. McCrae KR, Feinstein DI, Cines DB. Antiphospholipid antibodies and antiphospholipid syndrome. In: Colman W, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Haemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, PA, USA: Lippincott Williams & Wilkins, 2001: 1339-56.
40. van Bodegraven AA, Schoorl M, Linskens RK, Bartels PC, Tuynman HA. Persistent activation of coagulation and fibrinolysis after treatment of active ulcerative colitis. Eur J Gastroenterol Hepatol 2002; 14: 413-18.
41. Abbas AK, Lichtman AH, Pober JS. Cellular and Molecular Immunology. Philadelphia, PA, USA: WB Saunders, 2000: 62.
42. Haltensten TS, Mollnes TE, Garred P, Fausa O, Brandtzaeg P. Surface epithelium related activation of complement differs in Crohn's disease and ulcerative colitis. Gut 1992; 33: 902-8.
43. Ueki T, Mizumo M, Uesu T, Kiso T, Nasu J, Inaba T, Kihara Y, Matsuoka Y, Okada H, Fujita T, Tsuji T. Distribution of activated complement, C3b, and its degraded fragments, iC3b/C3dg, in the colonic mucosa of ulcerative colitis (UC). Clin Exp Immunol 1996; 104: 286-92.
44. Ahrenstedt O, Knutson L, Nilsson B, Nilsson-Ekdahl K, Odlind B, Hallhren R. Enhanced local production of complement components in small intestines of patients with Crohn's disease. N Engl J Med 1990; 322: 1345-9.